TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
NCT ID: NCT01421511
Last Updated: 2018-08-29
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
666 participants
INTERVENTIONAL
2011-09-15
2013-01-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Approximately 100 to 140 sites globally will participate in this study. Patients with an ABSSSI caused by suspected or documented gram positive pathogen(s) at baseline will be randomized 1:1 to study treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.
NCT01170221
GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection
NCT01209078
Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)
NCT02378480
Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
NCT02066402
Comparative Study of NXL103 Versus Linezolid in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
NCT00949130
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TR-701 FA
• TR-701 FA IV followed by TR-701 FA tablets
TR-701 FA
* TR-701 FA 200 mg once daily in 250 mL sterile saline for injection as a 60 minute IV infusion
* TR-701 FA Tablets, 200 mg, orally once daily
Linezolid
• Linezolid IV followed by Linezolid Tablets
Linezolid
* Linezolid 600 mg IV Injection twice daily in 300 mL sterile saline for injection as a 60 minute IV infusion
* Linezolid Tablets, 600 mg, orally every 12 hours
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TR-701 FA
* TR-701 FA 200 mg once daily in 250 mL sterile saline for injection as a 60 minute IV infusion
* TR-701 FA Tablets, 200 mg, orally once daily
Linezolid
* Linezolid 600 mg IV Injection twice daily in 300 mL sterile saline for injection as a 60 minute IV infusion
* Linezolid Tablets, 600 mg, orally every 12 hours
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with Cellulitis/ erysipelas, major cutaneous abscess, or wound infections
Exclusion Criteria
* Severe sepsis or septic shock
* ABSSSI solely due to gram-negative pathogens
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Philippe G Prokocimer, MD
Role: STUDY_DIRECTOR
Trius Therapeutics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Trius investigator site 159
Dothan, Alabama, United States
Trius investigator site 103
Chula Vista, California, United States
Trius investigator site 143
Escondido, California, United States
Trius investigator site 105
La Mesa, California, United States
Trius investigator site 106
Long Beach, California, United States
Trius investigator site 157
Long Beach, California, United States
Trius investigator site 142
National City, California, United States
Trius investigator site 170
San Diego, California, United States
Trius investigator site 167
Santa Ana, California, United States
Trius investigator site 168
Stockton, California, United States
Trius investigator site 141
Sylmar, California, United States
Trius investigator site 139
Denver, Colorado, United States
Trius investigator site 137
Newark, Delaware, United States
Trius investigator site 166
Edgewater, Florida, United States
Trius investigator site 101
Columbus, Georgia, United States
Trius investigator site 138
Carmel, Indiana, United States
Trius investigator site 144
Owensboro, Kentucky, United States
Trius investigator site 150
Baton Rouge, Louisiana, United States
Trius investigator site 165
Eunice, Louisiana, United States
Trius investigator site 154
Boston, Massachusetts, United States
Trius investigator site 146
Springfield, Massachusetts, United States
Trius investigator site 136
West Roxbury, Massachusetts, United States
Trius investigator site 163
Royal Oak, Michigan, United States
Trius investigator site 153
Minneapolis, Minnesota, United States
Trius investigator site 149
Picayune, Mississippi, United States
Trius investigator site 164
Creve Coeur, Missouri, United States
Trius investigator site 160
Las Vegas, Nevada, United States
Trius investigator site 147
Teaneck, New Jersey, United States
Trius investigator site 140
Columbus, Ohio, United States
Trius investigator site 162
Lima, Ohio, United States
Trius investigator site 161
Rapid City, South Dakota, United States
Trius investigator site 155
Franklin, Tennessee, United States
Trius investigator site 145
Memphis, Tennessee, United States
Trius investigator site 169
Smyrna, Tennessee, United States
Trius investigator site 148
Houston, Texas, United States
Trius investigator site 352
Cludadela, Buenos Aires, Argentina
Trius investigator site 354
General Roriquez, Buenos Aires, Argentina
Trius investigator site 350
La Plata, Buenos Aires, Argentina
Trius investigator site 350
La Plata, Buenos Aires, Argentina
Trius investigator site 353
Luján, Buenos Aires, Argentina
Trius investigator site 354
Buenos Aires, , Argentina
Trius investigator site 355
Buenos Aires, , Argentina
Trius investigator site 351
Cludad Autonoma de Buenos Aires, , Argentina
Trius investigator site 358
La Plata, , Argentina
Trius investigator site 357
Mar del Plata, , Argentina
Trius investigator site 359
Paraná, Entre Rios, , Argentina
Trius investigator site 356
Rosario, , Argentina
Trius investigator 500
Cairns, Queensland, Australia
Trius investigator 501
Herston, Queensland, Australia
Trius investigator 503
Nambour, Queensland, Australia
Trius investigator 506
Southport, Queensland, Australia
Trius investigator 502
Woolloongabba, Queensland, Australia
Trius investigator 504
Woolloongabba, Queensland, Australia
Trius investigator 505
Richmond, Victoria, Australia
Trius investigator site 362
Belo Horizonte, MG, Brazil, Brazil
Trius investigator site 361
Belo Horizonte, MG, Brazil, Brazil
Trius investigator site 363
Porto Alegre, RS, Brazil, Brazil
Trius investigator site 364
Campinas, SP, Brazil, Brazil
Trius investigator site 361
Belo Horizonte, , Brazil
Trius investigator site 362
Belo Horizonte, , Brazil
Trius investigator site 365
Belo Horizonte, , Brazil
Trius investigator site 364
Campinas, , Brazil
Trius investigator site 366
Curitiba, , Brazil
Trius investigator site 367
Curitiba, , Brazil
Trius investigator site 369
Jaú, , Brazil
Trius investigator site 363
Porto Alegre, , Brazil
Trius investigator site 370
Porto Alegre, , Brazil
Trius investigator site 360
São Paulo, , Brazil
Trius investigator site 208
Dresden, Saxony, Germany
Trius investigator site 206
Quedlinburg, Saxony-Anhalt, Germany
Trius investigator site 204
Lübeck, Schleswig-Holstein, Germany
Trius investigator site 207
Berlin, , Germany
Trius investigator site 205
Hamburg, , Germany
Trius investigator site 380
Guadalajara, , Mexico
Trius investigator site 381
Guadalajara, , Mexico
Trius investigator site 382
Mexico City, , Mexico
Trius investigator site 383
Monterrey, , Mexico
Trius investigator 521
Otahuhu, Auckland, New Zealand
Trius investigator 520
Sydenham, Christchurch, New Zealand
Trius investigator site 216
Bydgoszcz, , Poland
Trius investigator site 211
Lodz, , Poland
Trius investigator site 214
Lublin, , Poland
Trius investigator site 213
Poznan, , Poland
Trius investigator site 215
Szczecin, , Poland
Trius investigator site 212
Warsaw, , Poland
Trius investigator site 292
Vsevolozhsk, Leningradskaya Oblast', Russia
Trius investigator site 287
Barmaul, , Russia
Trius investigator site 286
Irkutsk, , Russia
Trius investigator site 293
Lipetsk, , Russia
Trius investigator site 295
Moscow, , Russia
Trius investigator site 290
Moscow, , Russia
Trius investigator site 291
Moscow, , Russia
Trius investigator site 288
Moscow, , Russia
Trius investigator site 297
Novosibirsk, , Russia
Trius investigator site 285
Novosibirsk, , Russia
Trius investigator site 294
Saint Petersburg, , Russia
Trius investigator site 289
Saint Petersburg, , Russia
Trius investigator site 296
Saint Petersburg, , Russia
Trius investigator site 298
Tomsk, , Russia
Trius investigator 444
Worscester, Cape, South Africa
Trius investigator 443
Port Elizabeth, Eastern Cape, South Africa
Trius investigator site 442
Bloemfontein, Free States, South Africa
Trius investigator site 441
Blowmfontein, Free States, South Africa
Trius investigator 451
Centurion, Gauteng, South Africa
Trius investigator site 440
Gezina Pretoria, Gauteng, South Africa
Trius investigator 450
Pretoria, Gauteng, South Africa
Trius investigator 449
Pretoria, Gauteng, South Africa
Trius investigator 448
Dundee, KwaZulu-Natal, South Africa
Trius investigator 446
Middelburg, Mpumalanga, South Africa
Trius investigator 447
Breyten, Mpunalanga, South Africa
Trius investigator site 445
Benoni, , South Africa
Trius investigator site 273
Mataró, Barcelona, Spain
Trius investigator site 272
Alcorcón, Madrid, Spain
Trius investigator site 275
Majadahonda, Madrid, Spain
Trius investigator site 277
Barakaldo, Vizcaya, Spain
Trius investigator site 276
Madrid, , Spain
Trius investigator site 274
Santander, , Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sandison T, De Anda C, Fang E, Das AF, Prokocimer P. Clinical Response of Tedizolid versus Linezolid in Acute Bacterial Skin and Skin Structure Infections by Severity Measure Using a Pooled Analysis from Two Phase 3 Double-Blind Trials. Antimicrob Agents Chemother. 2017 Apr 24;61(5):e02687-16. doi: 10.1128/AAC.02687-16. Print 2017 May.
Nathwani D, Corey R, Das AF, Sandison T, De Anda C, Prokocimer P. Early Clinical Response as a Predictor of Late Treatment Success in Patients With Acute Bacterial Skin and Skin Structure Infections: Retrospective Analysis of 2 Randomized Controlled Trials. Clin Infect Dis. 2017 Jan 15;64(2):214-217. doi: 10.1093/cid/ciw750. Epub 2016 Dec 21.
Powers JH 3rd, Das AF, De Anda C, Prokocimer P. Clinician-reported lesion measurements in skin infection trials: Definitions, reliability, and association with patient-reported pain. Contemp Clin Trials. 2016 Sep;50:265-72. doi: 10.1016/j.cct.2016.08.010. Epub 2016 Aug 13.
Shorr AF, Lodise TP, Corey GR, De Anda C, Fang E, Das AF, Prokocimer P. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2015 Feb;59(2):864-71. doi: 10.1128/AAC.03688-14. Epub 2014 Nov 24.
Lodise TP, Fang E, Minassian SL, Prokocimer PG. Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials. Antimicrob Agents Chemother. 2014 Dec;58(12):7198-204. doi: 10.1128/AAC.03509-14. Epub 2014 Sep 22.
Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014 Aug;14(8):696-705. doi: 10.1016/S1473-3099(14)70737-6. Epub 2014 Jun 5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TR701-113
Identifier Type: OTHER
Identifier Source: secondary_id
1986-010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.